Siagosidum (Siagoside) API Manufacturers & Suppliers

Siagoside (CAS 100345-64-0) is a naturally occurring glycosphingolipid found in the membranes of nerve cells. It is structurally classified within acidic glycosphingolipids, gangliosides, and other lipid-related categories. Investigational in nature, Siagoside has been studied primarily for potential applications in neurodegenerative and neurotraumatic conditions.

Clinically, Siagoside has undergone phase 2 trials for the treatment of Parkinson’s disease (PD), although no formal regulatory approval has been granted to date. Preliminary research shows it may exert neuroprotective effects, which has also led to investigations in severe spinal cord injury contexts. Preclinical studies in animal models demonstrated that Siagoside treatment resulted in a notable reduction in mortality—approximately 52%—following ischemic insult induced by unilateral carotid artery ligation, suggesting potential for mitigating ischemic neuronal damage.

While detailed pharmacodynamics and mechanism of action data are not fully characterized, Siagoside’s involvement in nerve cell membrane composition implies roles in cell growth, development, and repair processes. It may influence neuronal survival pathways or membrane repair mechanisms, consistent with its classification as a neuroprotective agent.

Key ADME parameters for Siagoside, including absorption, distribution, metabolism, and excretion profiles, have not been extensively documented in publicly available data. Safety and toxicity profiles remain under evaluation, with no comprehensive clinical safety data published. Investigational status necessitates cautious consideration regarding toxicity, drug interactions, or long-term effects.

Siagoside is sometimes identified by the developmental code Sygen or AGF 2 in research contexts. Ongoing development and clinical validation are required before any therapeutic claims or marketing authorizations can be established.

When sourcing Siagoside as an active pharmaceutical ingredient (API), attention should be given to purity specifications consistent with neuropharmaceutical-grade lipids. Suppliers must provide detailed analytical characterization, including confirmation of chemical identity, absence of contaminants, and stability data to ensure equivalency for investigational or research use. Regulatory compliance with Good Manufacturing Practices (GMP) is advisable for APIs intended for clinical trial supply.